Joseph Beaulieu files SEC Form 4 disclosures for Epizyme, Inc.. They have made 1 open-market trade across 1 company since 2019, most recently 2022-08-12.
CIK 0001766032
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EPZM | 21,895 | $32K |
Shares reported on the most recent Form 4, priced at the 2022-08-16 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EPZM | SELL · 10b5-1 | 2022-02-07 | 2022-02-09 | $1.50 | $333 | -9.8% | -21.4% | -65.7% |
| EPZM | SELL · 10b5-1 | 2022-02-02 | 2022-02-04 | $1.37 | $941 | +7.3% | -3.3% | -55.4% |
| EPZM | SELL · 10b5-1 | 2021-02-04 | 2021-02-05 | $11.21 | $3K | -4.0% | -19.3% | -38.8% |
| EPZM | SELL · 10b5-1 | 2020-06-26 | 2020-06-30 | $16.15 | $5K | -7.2% | -13.1% | -24.6% |
| EPZM | SELL · 10b5-1 | 2020-03-25 | 2020-03-26 | $15.28 | $3K | -11.1% | +3.2% | -2.7% |
| EPZM | SELL | 2020-03-03 | 2020-03-05 | $22.18 | $22K | -18.4% | -30.2% | -20.4% |
| EPZM | SELL · 10b5-1 | 2020-01-24 | 2020-01-27 | $24.63 | $8K | +1.6% | +1.0% | -18.4% |
| EPZM | SELL · 10b5-1 | 2019-09-03 | 2020-09-03 | $12.81 | $19K | -0.5% | -4.9% | +4.3% |
| EPZM | SELL · 10b5-1 | 2019-06-13 | 2019-06-14 | $12.10 | $2K | +9.4% | +16.2% | +3.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.